ADVANZ PHARMA is a specialty pharmaceutical company headquartered in London, with an operations centre of excellence in Mumbai, commercial affiliates in North America, Europe and Australia, and an established global network of commercial partners throughout the rest of the world. With an agile and experienced team, including direct sales, marketing and medical capabilities across many of Europe’s major markets, ADVANZ PHARMA supplies, innovates and enhances the critical medicines patients depend on, ensuring continued patient access and improving health outcomes.
The acquisition is to be effected by way of a members’ scheme of arrangement under Jersey company law. The acquisition is subject to various regulatory approvals and is expected to close in Q2 of 2021.
The global Appleby team was led by Appleby Partner Andrew Weaver and Senior Associate Kevin McQuillan. Senior Associate Daniel Healy and Trainee Angharad Prescott also assisted. Appleby has worked alongside White & Case LLP and Fasken Martineau DuMoulin LLP.
Speaking on the transaction Appleby Partner Andrew Weaver commented: “I am very pleased that we have been able to support Advanz Pharma on this next stage of the company’s development, following our work with the company on a series of transformative transactions over the years. This transaction showcases Appleby’s strength as a leading firm in public and private M&A and court regulated transactions.”
Kevin McQuillan added: “Having worked with the Advanz Pharma team for a number of years it is very pleasing to see them embark on this new chapter with Nordic. For our team this is the latest high profile public M&A mandate following a very active 2020 which builds on the market leading experience of our Jersey M&A team, particularly in takeovers by way of members’ scheme of arrangement.”
Appleby’s Merger and Acquisitions (M&A) team is well-positioned to advise clients on a wide range of M&A activities in the offshore region. Its unique jurisdictional reach means that Appleby is able to advise clients on complex, cross-border transactions involving the offshore jurisdictions that are most often encountered. The team regularly work with FTSE 100 and Fortune 500 companies around the globe and those with financial interests in them, to help them deploy strategic growth and restructuring initiatives, whether involving single jurisdictions or complex multi-jurisdictional, multi-disciplinary transactions.